Atossa Therapeutics (BMV:ATOS *) - Stock Price, News & Analysis

ATOS * Stock Overview

A clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. More details

ATOS * fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the MX market

Currently unprofitable and not forecast to become profitable over the next 3 years

Atossa Therapeutics, Inc. Competitors

Jacobio Pharmaceuticals Group

SEHK:1167

HK$1.2b

Shanghai Rightongene Biotechnology

SHSE:688217

CN¥1.1b

Instil Bio

NasdaqCM:TIL

US$193.8m

Gossamer Bio

NasdaqGS:GOSS

US$159.0m

Price History & Performance

Summary of all time highs, changes and price drops for Atossa Therapeutics
Historical stock prices
Current Share Price	US$27.00
52 Week High	US$38.35
52 Week Low	US$12.30
Beta	1.23
11 Month Change	-5.10%
3 Month Change	-1.82%
1 Year Change	110.94%
33 Year Change	-38.47%
5 Year Change	n/a
Change since IPO	-51.79%

Recent updates

Shareholder Returns

	ATOS *	MX Biotechs	MX Market
7D	5.9%	0%	0%
1Y	110.9%	0%	0%

Return vs Industry: ATOS * exceeded the MX Biotechs industry which returned 12.1% over the past year.

Return vs Market: ATOS * exceeded the MX Market which returned -4.7% over the past year.

Price Volatility

Is ATOS *'s price volatile compared to industry and market?
ATOS * volatility
ATOS * Average Weekly Movement	9.0%
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: ATOS *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: ATOS *'s weekly volatility (9%) has been stable over the past year, but is still higher than 75% of MX stocks.

About the Company

Founded	Employees	CEO	Website
2008	12	Steve Quay	www.atossatherapeutics.com

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs.

Atossa Therapeutics, Inc. Fundamentals Summary

How do Atossa Therapeutics's earnings and revenue compare to its market cap?
ATOS * fundamental statistics
Market cap	Mex$3.27b
Earnings (TTM)	-Mex$546.61m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-6.0x

P/E Ratio

Is ATOS * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATOS * income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$26.91m
Earnings	-US$26.91m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.21
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ATOS * perform over the long term?

See historical performance and comparison

ATOS * Stock Overview

Risk Analysis

Atossa Therapeutics, Inc. Competitors

SEHK:1167

HK$1.2b

SHSE:688217

CN¥1.1b

NasdaqCM:TIL

US$193.8m

NasdaqGS:GOSS

US$159.0m

Price History & Performance

Recent News & Updates

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results

Atossa Therapeutics, Inc Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Recent updates

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results

Atossa Therapeutics, Inc Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Atossa Therapeutics Grants Additional Patent Protection for Endoxifen

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Forecast to breakeven in 2026

Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

No longer forecast to breakeven

Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial

No longer forecast to breakeven

Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Independent Director recently bought Mex$730k worth of stock

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer

Independent Director recently bought Mex$730k worth of stock

Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient

Atossa Therapeutics Regain Compliance with Nasdaq Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Less than half of directors are independent

Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors

Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Forecast to breakeven in 2026

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Insider recently sold Mex$564k worth of stock

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Atossa Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Atossa Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Atossa Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Shareholder Returns

Price Volatility

About the Company

Atossa Therapeutics, Inc. Fundamentals Summary

0.0x

-6.0x

Earnings & Revenue